The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.  Claims of ...

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

Demand for Novo Nordisk A/S’s weight-loss blockbuster Wegovy is getting a boost in the UK from an unexpected corner: ...

He commented: “I want you to know I don’t want Novo Nordisk… and the reason that is because if there’s going to be talk about ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...